Skip to main content
. 2022 Feb 7;322(3):E307–E318. doi: 10.1152/ajpendo.00234.2021

Figure 5.

Figure 5.

Sacubitril does not alter β-cell and α-cell mass in Glp1r+/+ or Glp1r−/− mice. β-Cell mass (A and C) and α-cell mass (B and D) at the end of the 8-wk treatment period in VEH-CTL (n = 6), STZ-CTL (n = 9), and STZ-SAC (n = 8) groups of male Glp1r+/+ mice (A and B) and VEH-CTL (n = 8), STZ-CTL (n = 9), and STZ-SAC (n = 8) groups of male Glp1r−/− mice (C and D). E: representative images showing β cell (insulin; green), α cell (glucagon; red), and nuclei (blue) staining in pancreata from VEH-CTL (left), STZ-CTL (middle), and STZ-SAC (right) groups of male Glp1r+/+ (top) and male Glp1r−/− mice (bottom); scale bar = 50 μm. *P ≤ 0.05 (analyzed using one-way or Brown–Forsythe ANOVA followed by Dunnet’s multiple comparisons test). Data are means ± SE. GLP-1R, glucagon-like peptide-1 receptor; SAC, sacubitril; STZ, streptozotocin; VEH, vehicle.